• SGTM entered packaging agreement with Old Castle Lawn & Garden to supply large Midwest home improvement chains
• Old Castle Lawn & Garden parent company CRH employs 80,300 people at more than 3,100 locations across 30 countries
• SGTM dispatched team to assess damage from Hurricane Laura, one of the strongest in history
• SGTMS’s Q2 results nearly doubled from Q1 to $12.3 million in revenue, $3.4 million in gross profit

As nationwide demand for environmentally sustainable solutions for waste increases, Sustainable Green Team (OTC: SGTM) –a leading provider of environmentally beneficial solutions for tree and storm waste disposal—continues to expand its footprint in the U.S. through a packaging agreement between its subsidiary Mulch Manufacturing Inc. and Old Castle Lawn & Garden to supply large home improvement chains in the Midwest. The recent agreement with Old Castle Lawn & Garden is the latest in a series of strategic moves in line with SGTM’s corporate strategy, which combines operation expansion, strategic acquisitions and internal investment—moves that have enabled the company to expand and profit at a time of global economic contraction.

As a wholly-owned subsidiary of CRH, Old Castle Lawn & Garden provides architectural products that include concrete masonry and hardscapes, packaged cement mixes, packaged lawn and garden products. Its parent company CRH is a leading global diversified building materials group that employs over 80,300 people at more than 3,100 locations across 30 countries (https://ibn.fm/tCAtD).

“I am honored to have been engaged by Old Castle Lawn & Garden and to secure a packaging agreement with this global company, increasing our strategic partnerships,” said SGTM CEO and Director Tony Raynor in recent statements (https://ibn.fm/9olTc).

SGTM provides environmentally-beneficial solutions for tree and storm waste disposal created by hurricanes, ice storms and floods into useful organic products that benefit the environment. Through its subsidiaries, the company provides tree services that include debris hauling, biomass recycling, waste removal, mulch manufacturing, packaging and sales, and most recently the production of playground surface material.

Expert predictions forecasting a very active storm season for Florida are coming to fruition (https://ibn.fm/H0Awm), evidenced by the extent of the damage created by Hurricane Laura, considered to be one of the strongest hurricanes on record as measured by maximum sustained winds (https://ibn.fm/s7tBO). SGTM recently reported that it dispatched its National Storm Recovery Ltd. team to assess the damage and is still on site in impacted areas. Live video coverage of the company’s strategic relief efforts can be viewed online through its social media channels (https://ibn.fm/u24kU).

STGM has been rapidly growing despite a worldwide economic slowdown that has seen millions of businesses closed. The company’s impressive Q2 results almost doubled during the quarter and include over $12.3 million in revenue and $3.4 million in gross profit https://ibn.fm/n825Y. As “stewards of the environment” SGTM plans to continue expanding its operations and diversifying revenue streams amid a growing business landscape that is experiencing increased demand for their organic, sustainable and environmentally-friendly products.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/177U7.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Sales of wellness supplements surge 35% year on year, while mood enhancers report almost 10% growth
• As health and wellness awareness rises, SHRG ideally positioned to capitalize on growing momentum
• Company features proprietary products that promote well-being, happiness

Recent research conducted by SPINS, a data-driven company delivering insights about the health and wellness industry, reveals that the market for stress-relieving and mood-enhancing supplements are reporting double-digit growth compared to the previous year. With its exclusive wellness supplements product line designed to promote happiness and elevate lives, Sharing Services Global (OTCQB: SHRG) looks to be ideally positioned to leverage this upward trend as people place more importance on health and well-being.

The SPINS research shows that for the first seven months of 2020, the sales of supplements that help consumers manage stress, a category that includes mood support and sleep products, have increased by staggering 35% year on year. At the same time, mood support supplements reported a 9.6% growth for the first seven months of 2020 compared to the same period in 2019 (https://ibn.fm/obKAV).

Sharing Services is committed to developing brands specially designed to elevate the lives of consumers by delivering exceptional experience through premium products that assist in enhancing mood and reducing levels of stress while increasing levels of energy. With that focus in mind, SHRG looks to be ideally positioned to benefit from the emerging market trend. The company’s functional product lines include beverages and wellness supplements that feature proprietary D.O.S.E. formulation, uniquely developed to increase levels of four essential hormones – dopamine, oxytocin, serotonin and endorphins –associated with well-being and happiness. The compounds also bring other potential health benefits such as suppressing appetite and boosting the immune system.

SHRG is committed to upgrading its wellness product offering and continually introduces new products. But the company is not stopping there. SHRG branched out to develop an all-natural nootropic supplement called Xanthomax, featuring proprietary formulation uniquely designed to stimulate what the company calls D.O.S.E. response in the brain, boosting energy, motivation and optimism.

Nootropics are novel functional supplements, often called smart drugs, that enhance brain function and cognitive optimization as they allow more effective information processing. As a nutritional supplement, Xanthomax contains xanthohumol, one of the most powerful antioxidants, which also helps the body release oxytocin, a happiness-inducing hormone.

SHRG’s wellness product line is formulated and distributed by the company’s wholly owned subsidiary Elevacity and distributed by its Elepreneurs, a network of independent, home-based entrepreneurs. Elevacity collaborates with a team of scientists, doctors, pharmacists and food experts to develop powerful, all-natural functional beverages and health supplements, while Elepreneurs are tasked with the distribution of these innovative products through health and wellness aware, entrepreneurial community.

For more information, visit www.SHRGInc.com, www.Elevacity.com or www.Elepreneur.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• PacRoots Cannabis entered into a 60:40 joint-venture with Rock Creek Farms to plant premium hemp CBD plants on 100-acre site in British Columbia
• As of mid-June, approximately 130,000 seedlings have been planted with initial harvest set to take place October 15, 2020
• Initial harvest expected to yield between 500,000-700,000 pounds of biomass
• Totality of harvest yield is already under sale to local processor at fair market rate
• Proceeds from JV will initially go towards repaying PacRoots’ capital contribution with profits thereafter split along terms of the JV

PacRoots Cannabis (CSE: PACR), a Canada-based company dedicated towards producing premium-quality strains and products by leveraging a genetics-focused approach, has recently provided an update on its 100-acre commercial hemp operation located in the ‘Golden Mile’ area in the South Okanagan Valley in British Columbia (https://ibn.fm/xtZNq). Pursuant to a press release published on May 29, 2020, PacRoots entered into a binding letter of intent with Rock Creek Farms to take a 60% stake in a joint venture with the intent to plant hemp CBD seedlings on 100 acres of prime arable land, with PacRoots providing $450,000 in capital and Rock Creek Farms contributing the commercial leases to the growing space.

The agreement was immediately preceded by an industrial hemp license issued by Health Canada on May 22, 2020, which permitted the operational JV to cultivate, sell, import, export, possess and process industrial hemp on the leased land until March 15, 2021.

Planting commenced on the site in mid-June, with approximately 130,000 premium hemp CBD plants currently in the ground across the two 50-acre parcels comprising the site. Seedlings have been planted systematically in rows in the field after spending the first month in greenhouses, which has enabled the Company to ensure optimal growth while minimizing environmental influences during the early stage of the process.

“The Joint Venture team has been extremely busy preparing and planting the 100 acres with Hemp CBD cultivars,” said PacRoots Cannabis Corp. President and CEO Patrick Elliot. “We are thrilled with the short-term progress, making it possible for a 2020 production scenario to cultivate industrial Hemp in the ‘Golden Mile’. Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions. It will be an exciting outdoor growing season for the Joint Venture as we anticipate a successful harvest in the fall.”

PacRoots and Rock Creek Farms have deployed several traditional and customized hemp farming techniques to help ensure the quality of the end-product being cultivated on the site. A complex irrigation system has been installed to help ensure direct nutrient and spring water delivery to each plant site; cultivars measuring up to 18 inches have been systematically planted to provide the maximum opportunity for growth and resilience, while row compaction procedures and weed control processes have been adopted to enable a successful harvest.

Harvesting is now expected to begin on October 15, 2020 with an initial projected yield of 500,000 – 700,000 pounds of biomass. The totality of the product from the plantation has already been placed under sale contract with a processor at a fair market value.

Profits from the joint venture will be distributed first to PacRoots until its capital contribution has been repaid, and thereafter in accordance with the interest in the join venture held between PacRoots Cannabis and Rock Creek Farms.

For more information, visit the company’s website at www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Mobius partners with UltraPlay to enhance customer engagement
• UltraPlay at forefront of iGaming industry, provides widest eSports betting coverage in industry
• Partnership is clear indication of Mobius’s strong position coming straight out of gate

Mobius Interactive, an online gaming operator providing a variety of unique offerings catering to diverse demographic groups, has partnered with UltraPlay, a leading eSports and iGaming platform, to attract a global network of high-net-worth gamers. The two companies are working together to enhance customer engagement through the use of loyalty and gamification programs.

UltraPlay, an advanced-betting solutions provider, has been at the forefront of the iGaming industry for the past nine years, offering winning turnkey betting solutions and providing global leadership in the eSports B2B market. Awarded six times for its overall eSports betting solutions, the company is known as the leading eSports odds and platform provider.

The first company to offering live betting on eSports, UltraPlay today provides the widest eSports betting coverage in iGaming. Mobius’s partnership with the industry innovator and leader is a clear indication of its strong position coming straight out of the gate.

Slated for a launch this month, Mobius appears anything but new with its three differentiated brand offerings and joint ventures with more than 600 VIP and Master gaming affiliates. The company’s management team has been at the helm of the launch of more than 30 successful products within the last three years, and its partnership with UltraPlay is a key factor in this month’s kickoff.

Currently, Mobius is partnering with UltraPlay to offer more than 34 unique games and sports betting available 24/7. Mobius’ sports betting product has a wide range of functionalities, mystery jackpots, cutting-edge tech and live and pre-match odds. In addition, the company’s live casino games are compatible with desktop, smartphone, laptop and tablet devices and can accommodate any number of players at any time.

Mobius Interactive is an online gaming operator featuring a variety of unique offerings catering to diverse demographic groups. Mobius Interactive’s team has extensive senior-management experience across business-to-consumer (“B2C”) and business-to-business (“B2B”) marketing in the iGaming industry, specializing in eSports, sports betting, casino and live casino. In partnership with leading and award-winning eSports and iGaming platform Ultra Play, Mobius Interactive seeks to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance engagement by leveraging state-of-the-art customer relationship management systems and joint ventures with more than 600 VIP and master-gaming affiliates.

For more information, visit the company’s website at www.MobiusInteractive.Ltd.

NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Pharmaceutical industry services provider Trxade Group Inc. presented an overview of the company’s structure and strategy at this month’s LD 500 invitational microcap investor summit
• The investor summit was a virtual gathering place during the ongoing pandemic, providing brand and industry information through webcasts to more than 20,000 attendees representing hundreds of companies
• Trxade Group is dedicated to helping its growing network of independent pharmacies compete with big box chains through a supply chain trading platform that delivers transparent product pricing and availability information
• Trxade Group is also developing its nascent B2C operations with Telehealth services that link home-bound or office-bound patients to board-certified physicians in a low-cost model

A Kaiser Family Foundation (“KFF”) poll conducted last year found that 24 percent of its respondents had difficulty affording prescription drugs and 29 percent of all adults reported not taking their medicines as prescribed during the previous year because of the cost, relying instead on strategies such as not filling a prescription, taking an over-the-counter drug instead, or cutting pills in half or skipping a dose (https://ibn.fm/1v0gN). As the COVID-19 pandemic was just beginning to explode on American soil this spring, The Hill reported 34 million people knew at least one friend or family member who died in the last five years because they could not afford the medication to treat their condition (https://ibn.fm/ygyYE).

The pandemic has made access to reasonably priced medicine and medical supplies more critical than ever as people seek ways to maintain their care while limiting their exposure to infection from a potentially deadly new virus. Before the virus even appeared on the international scene, pharmaceutical supplies and services provider Trxade Group (NASDAQ: MEDS) was busy building a supply chain trading platform that supports small, community-based pharmacies trying to compete with national chains, and services that help consumers use available smart technology to consult with physicians and obtain their medications without having to leave home.

Trxade Group’s platform thrives on drug pricing and availability transparency for its B2B model while taking advantage of telehealth-friendly insurer policy shifts under its B2C model.

“If you look at a typical independent pharmacy today, it is an owner-operated retail establishment that doesn’t have the bandwidth or resources to shop around for product availability and pricing. Of course, … the Affordable Care Act is today speaking of lowering the reimbursement in an effort to save money. The solution is Trxade,” CEO Suren Ajjarapu said during a webcast company presentation as part of this month’s LD 500 invitational microcap investor summit (https://ibn.fm/oIB8N). “Trxade provides solutions to these independent pharmacies that are losing money or looking for alternatives when it comes to procurement of pharmaceuticals.”

Such services are particularly important when drugs are in short supply, and when demand is driving up the cost of the products.

Ajjarapu said Trxade recognizes it is serving around 15 million patients through the medium of over 11,700 independent pharmacies in its subscription network, which is why its B2C operations, led by its Bonum Health Hub portal, are so vital.

The health hub provides patients with telemedicine access to physicians at a fraction of the cost they would typically incur for doctor visits under their insurance plans, he said. And the company’s network of pharmacy businesses, paired with its app-accessible DelivMeds same-day / mail order pharmaceuticals delivery service, make it easier for patients to have medications delivered without having to go to the store to obtain them (https://ibn.fm/9VbJC).

“Of course our B2C platform is at a nascent stage when compared to other telemedicine portals out there, but (with) the unique nature of same-day drug delivery using our network,” Ajjarapu said. “Our vision there is, for non-emergency services or health needs, patients should never leave the house, should be able to talk to the doctor, get the drugs or meds delivered directly to their home or office.”

Ajjarapu told attendees at the virtual summit that the company’s capital structure enables reasonable earnings per share relatively quickly, and significant potential for return on investment because of the company’s structure and diverse sources of revenue.

“And that’s the key differentiator of us,” he said.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• World Federation of Direct Selling Associations reports healthy growth
• Wellness continues to be leader in U.S. space, where SHRG continues to attract customers, entrepreneurs with inclusive Blue Ocean strategy
• Strategy proves successful as reflected in robust fundamentals SHRG continues to post

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the direct-selling industry and network marketing is well positioned within the industry, which continues to record healthy growth, as reported by the World Federation of Direct Selling Associations (“WFDSA”) (https://ibn.fm/0aA7e). In its latest report, “2019 Direct Selling Business Results,” the WFDSA announced that worldwide retail sales showed a year-over-year sales increase of 1.4% compared to 2018 while growing at a healthy pace in the long term with five-year CAGR of 2.3% (excluding China).

Founded in 1978 as the leading international, nongovernmental, voluntary organization representing the global direct-selling industry in more than 170 countries, WFDSA has been publishing annual reports to inform its members and the general public about the latest trends shaping the industry. Other numbers of note in the report included the global sales force totaling 119.9 million independent representatives/distributors, a figure that includes more than 59 million independent representatives who are actively working to build their direct-selling businesses either as a full-time career or part-time to earn supplemental income.

“U.S. direct selling revenue not only remained stable during the past four years; it also offered many opportunities for growth,” said Ben Gamse, U.S. DSA senior marketing research manager. Direct selling enjoys a broad, diverse appeal, and is especially welcomed among younger generations of Americans who are pursuing flexible entrepreneurial opportunities (https://ibn.fm/xKqkP).

The WFDSA report also shows that wellness —the product category where SHRG operates — continues to be the leader in the U.S. direct-selling landscape with 36% of total sales. The report notes several reasons for this success. Customers are allured by the aspiration to improve their health and wellness, but they also appreciate highly personalized customer experiences that distributors provide as well as their enthusiasm for the products. A sense of community is a big part of that shopping and entrepreneurial experience.

This is precisely the strength of SHRG. The company not only operates in the most lucrative segment of the direct-selling market, but its whole philosophy is also centered around elevating lives of consumers and home-based entrepreneurs by distancing from cut-throat competition and following Blue Ocean strategy based on putting opportunities in the hands of its independent representatives, called Elepreneurs, and empowering them to take the reins on their future. SHRG nurtures people and community and creates high-quality, innovative products and success comes as a result of that. This unique approach is appreciated by consumers as reflected in the healthy financials the company continues to post.

The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Two of its primary divisions include Elevacity Holdings LLC., the parent of its wholly owned subsidiary, Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC., the parent of its wholly owned subsidiary, Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line.

For more information, visit the company’s website at www.SHRGInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020
• 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate in Phase 2b/3, helping mitigate the risks involved with its drug development
• The merger with 180 Life Sciences will enable KBL Merger Corp. IV to enter a market expected to double in size by 2027
• 180 Life Sciences is growing its patent portfolio through several preclinical studies beginning in two additional areas of inflammatory novel drug studies

Special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) completed its IPO in June 2017. The corporation raised $115 million intending to find and acquire a company with a strong value proposition primarily in the United States healthcare or healthcare-related industry.

In July 2019, KBL Merger Corp. IV signed a definitive business combination agreement for a merger with 180 Life Sciences Corp. (formerly known as CannBioRx Life Sciences Corp.), contingent on approval from KBL Merger Corp. IV. In June 2020, KBL Merger Corp. IV had completed bridge financing for the acquisition of 180 Life Sciences, which was valued by KBL at $175 million. KBL utilized share swapping to carry out the purchase.

The business combination is due to close during the fourth quarter of 2020. After the merger is complete, the company will be listed on the NASDAQ Capital Market under the ticker ‘ATNF.’ The bridge financing completion is expected to be used as working capital to complete the merger and used to advance the company’s clinical programs.

180 Life Sciences Research on Inflammation

180 Life Sciences Corp. is working on research to solve one of the world’s most significant drivers of disease – inflammation. The company currently has three programs developing novel drugs in different areas of study regarding inflammation.

The novel drug developments are currently in the areas of:

• Fibrosis and Anti-TNF
  • Dupuytren’s disease (Phase 2b/3 trial) – top-line data is expected by the fourth quarter of 2021.
  • Frozen Shoulder (Phase 2b trial) – scheduled to be initiated by the third quarter of 2021.
  • Post-Operative Cognitive Deficit (“POCD”) (Phase 2 trial) – anticipated to begin in the fourth quarter of 2021.
  • Liver Fibrosis and Nonalcoholic Steatohepatitis (“NASH”) (Preclinical Study) – set to begin late 2020.
• Inflammatory Pain
  • The research for inflammatory pain is currently in the Preclinical Study status, and aims to discover novel compounds to treat chronic inflammatory pain.
• A7nAChR
  • The research for the treatment of ulcerative colitis in ex-smokers, targeting the A7nAChR nicotine receptor in the body is currently in the Preclinical Study phase.

180 Life Sciences has mitigated the risks of its drug development through multiple programs at various stages of development. The company is actively decreasing costs and expediting the time to market by using grant funding and cost-effective trials internationally. Additionally, it has recruited teams with backgrounds in excellence, setting up the stage for success.

“Our scientific team has unparalleled expertise and a proven track record of developing unique drugs that improved the lives of millions of people and created companies that were later sold for billions of dollars,” KBL Merger Corp. IV CEO Dr. Marlene Krauss said when the closing of bridge financing was announced (https://ibn.fm/IhlKo). “We have assembled this world-class team to build a unique, global biotechnology company dedicated to developing novel drugs in a cost-effective manner.”

There has been an increase in demand for anti-inflammatory medication worldwide, and research indicates the market is expected to more than double within the next seven years. The value of the market in 2019 was $93.88 billion. The amount is expected to rise with a CAGR of 9.3% between 2020 and 2027, to reach $191.42 billion (https://ibn.fm/ohab2). These numbers are projected for the development of drugs for the treatment of autoimmune inflammatory diseases. Ailments covered include arthritis, asthma, sinusitis, rheumatoid arthritis, and other inflammatory conditions.

For more information, visit the companies’ websites at www.180LifeSciences.com and www.KBLMerger.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

• Pure Extract Technologies focuses on extraction of volatile plant molecules
• Company has recently announced entry into functional mushroom market, providing extraction services
• Pure Extract applying for Natural Health Products site license with Health Canada, which will help ensure that high quality standards will be upheld while also lending Company sales entry into foreign markets
• Company is set to focus on development of tinctures, soft-gel products, followed by move into creating beverage formulations as well as oral and nasal sprays

Pure Extract Technologies, (“Pure Extracts”) a Pemberton, British Columbia-domiciled private plant extraction company, has a successful history as the supplier of choice for companies requiring extraction services for product development. Pure Extracts has leveraged its years of experience in the extraction of volatile plant molecules as well as its technical competence in creating multiple successful CPG products and brands, both of which have afforded the firm a significant competitive advantage as it seeks to augment its strategic focus by partnering with companies seeking to develop new and innovative mushroom-based products. With Pure Extracts now poised to enter the commercial cannabis sector, as well as a new vertical in functional mushrooms, the Company has seized the opportunity to reveal its upcoming business development strategy going forward (https://ibn.fm/D7upV).

As Pure Extracts positions itself to become the premier commercialization and manufacturing partner for functional companies going forward, the Company plans to center its initial product lines on functional mushroom products. In its bid to do so, the Company is applying for a Natural Health Products site license with Health Canada, which, once received, will enable Pure Extracts to begin producing clinical trial samples in its purpose-built Whistler, British Columbia-based extraction facility. As the Company adheres to EU Good Manufacturing Practices (“GMP”), its focus on quality processes will help ensure that oil will be extracted to the highest possible quality.

Canada’s ability to easily export around the world coupled with Pure Extracts’ GPP (Good Production Practices) facility makes Pure Extracts a natural partner for companies involved within the psychedelic and functional product sectors. Pure Extracts has reportedly already met with some success in the field, having signed several NDAs with functional product companies seeking to explore joint development strategies for prospective product launches in the fourth quarter of 2020.

Functional mushrooms are increasingly being used in a wide variety of healthcare and pharmaceutical products. The application of these mushrooms as a functional ingredient in the medical industry is helping propel further growth within the sector, with functional mushroom-derived molecules increasingly employed within health supplement formulations. As testament to their growing popularity, a recent study on the functional mushroom market carried out by research firm Reportlinker.com forecasts the sector to grow at an impressive 8.04% CAGR over the period between 2019-2025 (https://ibn.fm/6X5t1).

Pure Extracts’ functional and psychedelic product expansion plans are set to be strategically rolled out in three distinct phases. Initially, the Company will focus its efforts on functional mushroom extracts used as active ingredients in the development of tinctures and/or soft gels. By the fourth quarter of 2020, the Company anticipates that its extraction efforts will also encompass developing products utilized in the manufacture of beverage formulations as well as in the creation of nasal and oral sprays.

In the second half of 2021, Pure Extracts will look towards assisting in the extraction of psilocybin, an active substance commonly found in hallucinogenic mushrooms which has recently been trialed as an experimental treatment for neurological conditions such as depression (https://ibn.fm/HdYnL). The Company will seek to simultaneously bolster its research into the psychedelic mushroom space, an industry experiencing growing interest due to shrooms’ ability to stimulate or suppress the activity of neurotransmitters they are chemically similar to, causing users to experience a number of different effects, including euphoria (https://ibn.fm/O0Ct3).

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom at http://ibn.fm/Pure

• POAI subsidiary Helomics exec discusses the company’s quest to fight cancer
• Helomics tapping into the fast growing, billion-dollar AI in drug discovery market
• Pittsburgh-based company has been building foundational groundwork in cancer drug response profiling for two decades
• Helomics harnesses rich historic tumor data with the power of AI to test living tumor tissues

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that one of its executives, Helomics CIO Mark Collins, PhD, recently appeared on DojoLIVE! (https://ibn.fm/hSAn4). Helomics, a POAI subsidiary, applies artificial intelligence to its rich data gathered from more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies.

Collins addressed this powerful work during the DojoLive! Interview, which was titled, “Can We Cure Cancer with Artificial Intelligence?” During the interview, Collins observed that using computers to help discover new anti-cancer drugs has been a lifelong passion of his. “The last 20 years of my career, I’ve been trying to realize that vision of how the convergence of AI, data and biology can be used to discover new drugs,” he said.

Joining Helomics has been an important part of that journey, Collins said, noting that the Pittsburgh-based company has been around for some two decades. “The founder, Dr Paul Kornblith, developed an innovative approach to individualizing treatment by taking a piece of tumor from a patient’s body and growing it in the lab and testing drugs on it, and he had some amazing successes,” Collins said. “Over the past three years we’ve leveraged these assets, such as the data that the company has gathered over these 20 years of testing tumors on drugs to build an AI-driven drug discovery services company.

“So that’s kind of where we are today,” Collins continued, noting that the company mission and vision was partly fueled by the passion felt by company leaders and partly circumstances because it had already gathered the data. “What it comes down to, at Helomics we have a very nice convergence of data that we’ve gathered from testing live tumors outside of the patient’s body, on standard-of-care drugs you might get if you were diagnosed with cancer, together with access to outcome data.”

Collins noted that Helomics has a “massive collection of data . . . And we have AI,” he said. “And it’s that convergence of AI, the big data, if you will, and the biology, where we’re able to test drugs on living tumor tissue rather than some artificial system, that we really believe will revolutionize drug discovery and impact the patients of tomorrow.

Helomics is not alone in this application of AI to drug discovery, which a recent report from Markets and Markets indicated is valued at $1.4B by 2024 (https://ibn.fm/UbGbI), but does believe its unique platform offers significant value to Pharma companies.

Helping the patients of today, Collins explained, Helomics has a clinical test for ovarian cancer that harnesses the patient’s own tumor to guide treatment. He notes, “We grow the tumor in the lab, test drugs on it, we look at different mutations on the tumor, and then we. . . compare that with the data we have in our data base, and we feed that back to the oncologist to guide treatment. We don’t make a recommendation; we can’t prescribe the drug. But this information really helps the clinician to decide how best to individualize the drug choice for the patient.”

DojoLive! is a podcast and interview forum that brings together a roster of technology, business and thought leaders from a wide range of software companies and startups. The episode featuring Collins, titled “Can We Cure Cancer with Artificial Intelligence?”, is available for on-demand viewing on the DojoLIVE! website.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Cybin announces appointment of established pharma industry figure as new CEO
• Drysdale leverages 30 years of leadership, entrepreneurial experience in life-science space
• Announcement comes as Cybin sets out on path to profitability

Cybin Corp., an innovative life science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, has announced the appointment of Mr. Doug Drysdale as the company’s Chief Executive Officer. With more than three decades of experience, the new leader recognizes psychedelics as a major breakthrough in treating mental health conditions. Drysdale joins Cybin to pave the road for the company’s rapid growth, underpinned by the recent strong push for research and commercialization in the psychedelics sector.

“With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Cybin co-founder and Chief Operating Officer Paul Glavine. “We believe that his extensive health-care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances and expand our international presence. We believe his strong leadership experience will help focus Cybin during its initial path to profitability.”

With more than 30 years of successful entrepreneurial experience, Drysdale has led hundreds of business development transactions and executed 15 M&A deals in the international environment life-science sector. Drysdale’s unique skill set reflects both his executive and entrepreneurial experience honed as he led the turnaround of Norwich Pharmaceuticals, becoming the founding CEO of parent company Alvogen. In that role, he helped the company grow from inception to $450 million in five years with revenues generated across 35 countries and a product development pipeline of over 50 products for the U.S. market.

As a well-known figure in the pharma space, Drysdale was recognized by “Pharmaceutical Executive” magazine as a 2011 Emerging Leader and received the 2012 Ernst & Young Entrepreneur of the Year Award. He was also named the 2011 International Business Award Distinguished Honoree for Executive of the Year (Pharmaceuticals).

Drysdale holds a bachelor’s degree in microbial and molecular biology from the University of East Anglia in the United Kingdom. He brings to his new position a wealth of knowledge and experiences in the health-care sector. Previously, he served as director and CEO of Tedor Pharma, a contract manufacturing business featured in the 2020 Inc. 5000 list as one of the fastest-growing companies in the country. Prior to Tedor Pharma, Drysdale was chairman and CEO of Pernix Therapeutics, a life-science company that he helped grow from $80 million to an estimated $800 million, raising $465 million of capital.

Drysdale is quick to spot opportunities as they emerge. “I am beyond excited to be joining the Cybin team,” said Drysdale. “I believe Cybin’s business model and talented management team uniquely position the company to examine the efficacy of psychedelic-based therapies and delivery systems in treating mental illness and addiction disorders. I expect Cybin’s expanding development pipeline will allow Cybin to additionally explore a cost-effective and timely array of health-care alternatives. We will continue to organically grow our IP portfolio and shall be looking to add to our IP through accretive acquisitions.”

As a pioneer in pharmaceutical psychedelics, Cybin is poised to engineer the development of psilocybin-based medicine designed to potentially alleviate major depressive disorders. In the process, opening up a new path to rapid growth and sustainable profitability, seems inevitable.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin